JPMorgan analyst Anupam Rama raised his price target for Rigel Pharmaceuticals to $7 and reiterates an Overweight rating on the shares. The Tavalisse launch in chronic immune thrombocytopenia, progress on the follow-on indication of autoimmune hemolytic anemia, and potential outside the U.S. partnership progress should drive upside near- and long-term, Rama tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.